Xeris Biopharma — Third Quarter 2026 Earnings Summary

Xeris Biopharma reported third-quarter 2026 total revenue of $107.2 million, representing a 44% year-over-year increase driven primarily by a 93% surge in Recorlev net revenue to over $71 million. The company raised its full-year 2026 total revenue guidance to a range of $395 million to $405 million and increased its 2030 total revenue outlook to more than $1 billion. Key operational milestones included the full retirement of 2028 Convertible Notes, the initiation of the pivotal Phase 3 Cornerstone study for its investigational drug XP-8121 by year-end, and the granting of new patents for both XP-8121 and Keveyis.